Why is the Telix share price jumping 15% to a record high?

This healthcare stock is scaling new heights on Thursday. But why?

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is taking off on Thursday morning.

At the time of writing, the radiopharmaceuticals company's shares are up 15% to a record high of $14.46.

Why is the Telix share price rocketing?

Investors have been bidding the company's shares higher today in response to the release of a quarterly update after the market close on Wednesday.

According to the release, during the first quarter of FY 2024, Telix reported unaudited total revenue of US$114.9 million (A$175 million).

This represents a sizeable 18% increase on the US$97.1 million (A$148.1 million) that was recorded during the fourth quarter of FY 2023.

Management notes that its revenue was primarily generated from sales of Telix's prostate cancer imaging product Illuccix.

The vast majority of this revenue was from the United States market, with U.S. revenue growing by 18% quarter on quarter to US$111.8 million from US$95.1 million. This is a quicker growth rate than the 11% increase it recorded in US revenue between the third quarter and fourth quarter of FY 2023.

Guidance reaffirmed

Telix has reaffirmed the guidance it provided to the market in February.

It continues to expect FY 2024 revenue to be in the range of US$445 million to $465 million (A$675 million to $705 million at current exchange rates).

This represents an increase of approximately 35% to 40% over what was recorded in FY 2023.

Management also advised that it continues to expect its research and development (R&D) investment to increase by 40% to 50% for FY 2024. It notes that this includes external and internal costs funded by operating cash flow and is broadly in line with its revenue growth.

On track to achieve major milestones

Telix's managing director and CEO, Dr Christian Behrenbruch, was rightfully pleased with the company's progress and appears positive on its outlook. He commented:

The continued, consistent growth of our precision diagnostics business is further evidence of an effective market growth strategy for our prostate cancer franchise. The dual benefit of an early revenue stream, and the ability to fund our late-stage therapeutic programs ensures we are on track to achieve major milestones in 2024 including the progression of three drug approval submissions in the U.S. and the international expansion of our Phase III ProstACT GLOBAL therapy trial in prostate cancer, subject to requisite regulatory approvals.

The recently closed acquisitions of ARTMS, Inc. (ARTMS) and IsoTherapeutics Group, LLC (IsoTherapeutics) enhance the vertical integration of our business and differentiate Telix as a leading independent radiopharmaceutical company worldwide by adding manufacturing capabilities and facilities, and isotope production technologies to the Telix Group of companies.

The Telix share price is up 62% over the last 12 months.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »